The US Food and Drug Administration approved the drug after trials showed a lower rate of relapse in chronic inflammatory demyelinating polyneuropathy or withdrawal for any other reason.
A pooled analysis of the phase 3 BOREAS and NOTUS trials evaluated whether add-on dupilumab, given on top of triple inhaler therapy, improves health-related quality of life and respiratory symptoms in...
